![]() ![]() Brooks MA, Thomas L, Magi-Galluzzi C, Li J, Crager MR, Lu R et al.GPS assay association with long-term cancer outcomes: twenty-year risk of distant metastasis and prostate cancer-specific mortality. Impact of a Genomic Test on Treatment Decision in a Predominantly African American Population With Favorable-Risk Prostate Cancer: A Randomized Trial. Murphy AB, Abern MR, Liu L, Wang H, Hollowell CMP, Sharifi R, Vidal P, et al.Improving Risk Stratification Among Veterans Diagnosed With Prostate Cancer: Impact of the 17-Gene Genomic Prostate Score Assay. Lynch JA, Rothney MP, Salup RR, Ercole CE, Mathur SC, Duchene DA, et al.Use of a 17-Gene Prognostic Assay in Contemporary Urologic Practice: Results of an Interim Analysis in an Observational Cohort. Eure G, Germany R, Given R, Lu R, Shnidel AW, Rothney M, et al.Utility of the Oncotype DX ® Prostate Cancer Assay in Clinical Practice for Treatment Selection in Men Newly Diagnosed with Prostate Cancer: A Retrospective Chart Review Analysis. Dall’Era MA, Maddala T, Polychronopoulos L, Gallagher JR, Febbo PG, and Denes BS.Health economic impact and prospective clinical utility of Oncotype DX Genomic Prostate Score. Albala D, Kemeter MJ, Febbo PG, Lu R, John V, Stoy D et al.Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies. Knezevic D, Goddard AD, Natraj N, Cherbavaz DB, Clark-Langone KM, Snable J, et al.McGarrity received a Bachelor of Arts degree from the University of Notre Dame and began his career in commercial banking. McGarrity also had executive general management responsibility for a newly created business unit focused on interventional spine pain management. McGarrity spent 13 years at Stryker Corporation (NYSE: SYK) where he served in leadership roles in sales and marketing and led Stryker into new growth markets such as post-operative pain management, surgical fluid waste management and interventional pain management. McGarrity was the CEO of Nanosphere (NASDAQ: NSPH), a nanotechnology-based molecular diagnostics company, where he engineered an operational and strategic turnaround that resulted in its successful sale to Luminex (NASDAQ: LMNX) in 2016. McGarrity was most recently the CEO of Sterilis Medical. McGarrity has more than 25 years of experience in the healthcare industry with a unique combination of device, diagnostics and biotechnology experience. Simple bell curve helps you and your patient understand the patient’s risk relative to other patients of same clinical risk group.Clearly stratifies patient risk into lower or higher likelihood of disease progression. ![]() Helps determine the right level of treatment.The high-risk report provides a defined cut point with actionable information on treatment intensity 2 Risk of PCa-specific death within 10 years.Risk of high-grade (≥Grade Group 3) disease.The Genomic Prostate Score (GPS) test is the only commercially available test to provide all these endpoints:.Focuses on an actionable endpoint adverse pathology, with the most comprehensive definition.Predicts tumor aggressiveness to help inform the decision between active surveillance and immediate treatment.The low-risk report integrates clinical, pathological, and genomic insights into actionable information on active surveillance 1 For the next step in care Low-Risk Report ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |